Literature DB >> 22751860

[Modern therapy of psoriasis : evidence-based, patient-centered, goal-oriented].

W-H Boehncke1.   

Abstract

Psoriasis is a multifaceted and-due to its comorbidities-multi-system disease. This is reflected by the wide spectrum of therapeutic options. Recently, efforts have been made to define evidence-based therapeutic standards to provide orientation for dermatologists' treatment decisions. Costly innovative therapeutics as well as increased awareness of long-term safety issues has led to the definition of objective treatment goals. In this regard, patient-reported outcomes are highly relevant. Here, results of recent developments in the field of evidence-based, patient-centered, goal-oriented therapy of psoriasis are summarized.

Entities:  

Mesh:

Year:  2012        PMID: 22751860     DOI: 10.1007/s00105-012-2399-7

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  8 in total

Review 1.  Managing comorbid disease in patients with psoriasis.

Authors:  Wolf-Henning Boehncke; Sandra Boehncke; Michael P Schön
Journal:  BMJ       Date:  2010-01-15

2.  Quality of psoriasis care in Germany--results of the national study PsoHealth 2007.

Authors:  Matthias Augustin; Kristian Reich; Christine Reich; Sandra Purwins; Stephan Jeff Rustenbach; Ines Schäfer; Marc Radtke
Journal:  J Dtsch Dermatol Ges       Date:  2008-08       Impact factor: 5.584

3.  Therapy of psoriasis in childhood and adolescence - a German expert consensus.

Authors:  Michael Sticherling; Matthias Augustin; Wolf-Henning Boehncke; Enno Christophers; Silja Domm; Harald Gollnick; Kristian Reich; Ulrich Mrowietz
Journal:  J Dtsch Dermatol Ges       Date:  2011-05-18       Impact factor: 5.584

4.  Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction.

Authors:  Robert S Stern; Tamar Nijsten; Steven R Feldman; David J Margolis; Tara Rolstad
Journal:  J Investig Dermatol Symp Proc       Date:  2004-03

5.  [Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases].

Authors:  R Diel; B Hauer; R Loddenkemper; B Manger; K Krüger
Journal:  Z Rheumatol       Date:  2009-07       Impact factor: 1.372

6.  Translating psoriasis treatment guidelines into clinical practice - the need for educational interventions and strategies for broad dissemination.

Authors:  Alexander Nast; Ricardo Erdmann; Delano Pathirana; Berthold Rzany
Journal:  J Eval Clin Pract       Date:  2008-10       Impact factor: 2.431

7.  Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris.

Authors:  K Kragballe; K L Noerrelund; H Lui; J P Ortonne; G Wozel; T Uurasmaa; C Fleming; J L López Estebaranz; L I Hanssen; L-M Persson
Journal:  Br J Dermatol       Date:  2004-06       Impact factor: 9.302

8.  Definition of treatment goals for moderate to severe psoriasis: a European consensus.

Authors:  U Mrowietz; K Kragballe; K Reich; P Spuls; C E M Griffiths; A Nast; J Franke; C Antoniou; P Arenberger; F Balieva; M Bylaite; O Correia; E Daudén; P Gisondi; L Iversen; L Kemény; M Lahfa; T Nijsten; T Rantanen; A Reich; T Rosenbach; S Segaert; C Smith; T Talme; B Volc-Platzer; N Yawalkar
Journal:  Arch Dermatol Res       Date:  2010-09-21       Impact factor: 3.017

  8 in total
  2 in total

1.  [Depression and anxiety disorders among psoriasis patients: protective and exacerbating factors].

Authors:  K Bangemann; W Schulz; J Wohlleben; A Weyergraf; I Snitjer; T Werfel; G Schmid-Ott; D Böhm
Journal:  Hautarzt       Date:  2014-12       Impact factor: 0.751

Review 2.  A patient-centred approach to biological treatment decision making for psoriasis: an expert consensus.

Authors:  R Strohal; J C Prinz; G Girolomoni; A Nast
Journal:  J Eur Acad Dermatol Venereol       Date:  2015-09-14       Impact factor: 6.166

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.